The market for B7-H4 targeted therapies is projected to experience substantial growth in the coming years, driven by a rising incidence of cancer diagnoses, growing awareness of the B7-H4 biomarker, and an expanding pipeline of B7-H4-targeted treatments currently in clinical development.

针对B7-H4的靶向治疗市场预计将在未来几年实现显著增长，这一增长得益于癌症诊断率的上升、对B7-H4生物标志物认知度的提高，以及目前处于临床开发阶段的B7-H4靶向治疗药物管线的不断扩展。

LAS VEGAS

拉斯维加斯

,

，

July 24, 2025

2025年7月24日

/PRNewswire/ -- DelveInsight's

/PRNewswire/ -- DelveInsight的

B7-H4 Targeting Therapies Market Size, Target Population, Competitive Landscape & Market Forecast

B7-H4靶向治疗市场规模、目标人群、竞争格局与市场预测

report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as NSCLC, Ovarian Cancer, Endometrial Cancer, Triple Negative Breast Cancer, Biliary Tract Cancer, and others. The selected indications are based on approved therapies and ongoing pipeline activity.

报告包括对当前治疗实践、可治疗患者群体的全面了解，其中包含非小细胞肺癌、卵巢癌、子宫内膜癌、三阴性乳腺癌、胆道癌等主要适应症。所选适应症基于已批准的疗法和正在进行的研发管线活动。

The report also provides insights into the emerging B7-H4 targeting therapies, market share of individual therapies, and current and forecasted market size from 2020 to 2040, segmented into 7MM..

该报告还提供了对新兴的B7-H4靶向疗法、各疗法的市场份额以及2020年至2040年的当前和预测市场容量的见解，并按7MM进行了细分。

Key Takeaways from the B7-H4 Targeting Therapies Market Report

B7-H4靶向治疗市场报告的关键要点

As per DelveInsight's analysis, the total market size of B7-H4 targeting therapies in the 7MM is expected to surge significantly by 2040.

根据DelveInsight的分析，到2040年，针对B7-H4的疗法在七大市场（7MM）中的总市场规模预计将大幅增长。

The report provides the total potential number of patients in the indications, such as

该报告提供了适应症中潜在患者总数，例如

NSCLC, Ovarian Cancer, Endometrial Cancer, Triple Negative Breast Cancer, Biliary Tract Cancer

非小细胞肺癌、卵巢癌、子宫内膜癌、三阴性乳腺癌、胆道癌

, and others.

，以及其他。

Leading B7-H4 targeting therapies companies, such as

领先的B7-H4靶向治疗公司，如

AstraZeneca, Pfizer (Seagen), Mersana Therapeutics, GlaxoSmithKline, NextCure,

阿斯利康、辉瑞（Seagen）、Mersana Therapeutics、葛兰素史克、NextCure，

and others, are developing novel B7-H4 targeting therapies that can be available in the B7-H4 targeting therapies market in the coming years.

其他公司正在开发新型的B7-H4靶向疗法，这类疗法有望在未来几年内进入B7-H4靶向疗法市场。

Some of the key B7-H4 targeting therapies in the pipeline include

一些关键的B7-H4靶向疗法在研发管线中包括

Puxitatug samrotecan (AZD8205), Felmetatug vedotin, Emiltatug ledadotin, GSK5733584, LNCB74,

Puxitatug samrotecan (AZD8205)、Felmetatug vedotin、Emiltatug ledadotin、GSK5733584、LNCB74，

and others.

和其他人。

In

在

January 2025

2025年1月

,

，

the FDA granted an additional Fast Track Designation (FTD) to emiltatug ledadotin for the treatment of advanced or metastatic breast cancer in patients with human epidermal growth factor receptor 2 (HER2) low (IHC 1+ or IHC 2+/ISH–) or HER2-negative (IHC 0) disease, including triple-negative breast cancer (TNBC)..

FDA授予了emiltatug leddotin额外的快速通道指定（FTD），用于治疗HER2低（IHC 1+或IHC 2+/ISH–）或HER2阴性（IHC 0）的晚期或转移性乳腺癌患者，包括三阴性乳腺癌（TNBC）。

Discover which indication is expected to grab the major B7-H4 targeting therapies market share @

发现哪种适应症预计将占据主要的B7-H4靶向治疗市场份额 @

B7-H4 Targeting Therapies Market Report

B7-H4靶向治疗市场报告

B7-H4 Targeting Therapies Market Dynamics

B7-H4靶向治疗市场动态

The B7-H4 targeting therapies market is rapidly emerging as a promising frontier in immuno-oncology. B7-H4 is a member of the B7 family of immune checkpoint molecules that has been implicated in tumor immune evasion. It is highly expressed in a wide range of solid tumors, including

B7-H4靶向治疗市场正在迅速成为免疫肿瘤学领域的一个有前景的前沿。B7-H4是B7家族中的一种免疫检查点分子，已被证实与肿瘤免疫逃逸有关。它在多种实体瘤中高度表达，包括

breast, ovarian, endometrial, and non-small cell lung cancers

乳腺癌、卵巢癌、子宫内膜癌和非小细胞肺癌

, while its expression in normal tissues is relatively limited. This differential expression has made B7-H4 an attractive therapeutic target, particularly for

，而其在正常组织中的表达相对有限。这种差异性表达使得B7-H4成为了一个有吸引力的治疗靶点，特别是对于

ADCs, monoclonal antibodies, and T-cell engagers

抗体药物偶联物（ADCs）、单克隆抗体和T细胞衔接器

.

。

A key driver of the market is the

市场的一个关键驱动因素是

growing recognition of B7-H4's immunosuppressive role

日益认识到B7-H4的免疫抑制作用

within the tumor microenvironment, where it inhibits T-cell activation and contributes to immune escape. As immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 reach saturation in terms of patient eligibility and response, there is a strong push to identify novel checkpoints like B7-H4. Companies are now investing in .

在肿瘤微环境中，它抑制T细胞的激活并促进免疫逃逸。随着针对PD-1/PD-L1和CTLA-4的免疫检查点抑制剂在患者适用性和响应方面趋于饱和，人们正在大力推动寻找像B7-H4这样的新检查点。公司现在正投资于 。

developing B7-H4-targeted ADCs

开发针对B7-H4的抗体偶联药物（ADC）

, which utilize cytotoxic payloads to selectively eliminate B7-H4-expressing tumor cells, showing encouraging preclinical and early clinical results.

，它们利用细胞毒性载荷选择性地消除表达B7-H4的肿瘤细胞，显示出令人鼓舞的临床前和早期临床结果。

The

The

competitive landscape is witnessing increasing activity

竞争格局正在见证越来越多的活动

, with several biotech and pharmaceutical players entering this space through

，通过以下方式进入这个领域的生物技术和制药企业越来越多：

internal R&D or strategic collaborations

内部研发或战略合作

. Partnerships and licensing agreements are likely to intensify as companies seek to combine B7-H4 therapies with existing immunotherapies or targeted agents to enhance treatment efficacy. Additionally,

合作伙伴关系和许可协议可能会加强，因为公司寻求将B7-H4疗法与现有的免疫疗法或靶向药物相结合，以提高治疗效果。此外，

advancements in biomarker development

生物标志物开发的进展

are enabling better patient stratification, which is critical for B7-H4-targeting strategies, given its heterogeneous expression across tumor types and stages.

正在实现更好的患者分层，这对于B7-H4靶向策略至关重要，因为其在肿瘤类型和阶段中表达具有异质性。

Despite the enthusiasm, the market also faces several challenges. These include

尽管充满热情，但市场也面临若干挑战。这些挑战包括

limited understanding of B7-H4's broader biological functions, potential on-target off-tumor toxicities, and the need for robust companion diagnostics

对B7-H4更广泛的生物学功能、潜在的靶向非肿瘤毒性以及对可靠伴随诊断的需求了解有限

. Moreover,

此外，

clinical trials are still in early phases

临床试验仍处于早期阶段

, and long-term safety and efficacy data are lacking. Regulatory hurdles and competition from other novel checkpoints, such as

，并且缺乏长期的安全性和有效性数据。监管障碍以及来自其他新型检查点的竞争，例如

TIGIT, LAG-3, and TIM-3

TIGIT、LAG-3 和 TIM-3

, could also influence the pace and direction of market growth.

，也可能影响市场增长的速度和方向。

Overall, the B7-H4 targeting therapies market holds strong potential to reshape cancer immunotherapy, particularly for patients who are refractory to current checkpoint inhibitors. As clinical validation continues and combination strategies evolve, the coming years could witness a transformation in how immune escape mechanisms like B7-H4 are tackled in precision oncology..

总体而言，针对B7-H4的治疗市场有强大的潜力重塑癌症免疫疗法，特别是对于那些对当前检查点抑制剂无反应的患者。随着临床验证的继续和联合策略的发展，未来几年可能会见证在精准肿瘤学中如何应对像B7-H4这样的免疫逃逸机制的转变。

B7-H4 Targeting Therapies Treatment Market

B7-H4靶向治疗市场

B7-H4 has emerged as a promising biomarker and therapeutic target across several indications, including cancer, inflammatory disorders, autoimmune conditions, and organ transplant settings. It is currently under early-stage development, primarily for advanced solid tumors.

B7-H4 已成为多种适应症（包括癌症、炎症性疾病、自身免疫疾病和器官移植环境）中一个有前景的生物标志物和治疗靶点。目前，它尚处于早期开发阶段，主要针对晚期实体瘤。

Therapies targeting B7-H4 generally exhibit a manageable safety profile, with no infusion-related reactions reported. Common side effects include fatigue, neutropenia, anemia, neuropathy, and gastrointestinal disturbances. Adverse effects related to antibody-drug conjugates are consistent with those seen in traditional cytotoxic treatments..

针对B7-H4的疗法通常表现出可管理的安全性，未报告有输注相关反应。常见副作用包括疲劳、中性粒细胞减少、贫血、神经病变和胃肠道不适。与抗体药物偶联物相关的不良反应与传统细胞毒性治疗中所见的一致。

B7-H4-directed ADCs have demonstrated encouraging activity in various cancers, including bladder, ovarian, and breast tumors. There remains a significant unmet need for effective and well-tolerated targeted therapies in these cancers, especially among patients who have relapsed or become resistant to standard treatments..

B7-H4导向的ADC在包括膀胱癌、卵巢癌和乳腺肿瘤等多种癌症中展现出令人鼓舞的活性。这些癌症，尤其是那些复发或对标准治疗产生耐药性的患者，对于有效且耐受性良好的靶向疗法仍存在显著的未满足需求。

Learn more about the B7-H4 targeting therapies @

了解有关 B7-H4 靶向疗法的更多信息 @

B7-H4 Targeting Therapies Analysis

B7-H4靶向治疗分析

Key Emerging B7-H4 Targeting Therapies and Companies

关键的新兴B7-H4靶向疗法及公司

Several key players, including

包括几个关键球员，

AstraZeneca

阿斯利康

(Puxitatug samrotecan),

(普希塔图格·萨莫特坎),

Mersana Therapeutics

迈尔斯纳治疗学

(Emiltatug ledadotin),

(Emiltatug ledadotin),

Pfizer (Seagen)

辉瑞（Seagen）

(Felmetatug vedotin),

（Felmetatug vedotin），

GSK

葛兰素史克

(GSK5733584), and others, are involved in developing drugs for B7-H4 for various indications such as breast cancer, non-small cell lung cancer, and others.

(GSK5733584)等其他药物，也参与了针对B7-H4的药物开发，适应症包括乳腺癌、非小细胞肺癌等。

Felmetatug vedotin

维多汀

is an investigational antibody-drug conjugate (ADC) built on the vedotin platform. It consists of a human monoclonal antibody targeting B7-H4, linked to the cytotoxic agent monomethyl auristatin E (MMAE) through a protease-cleavable maleimidocaproyl valine citrulline (mc-vc) linker. This vedotin linker-payload technology has been clinically validated in several FDA-approved therapies, including brentuximab vedotin, enfortumab vedotin, and tisotumab vedotin.

是一种基于vedotin平台的在研抗体药物偶联物（ADC）。它由一种靶向B7-H4的人源单克隆抗体组成，通过蛋白酶可切割的马来酰亚胺己酰缬氨酸瓜氨酸（mc-vc）连接子与细胞毒性药物单甲基澳瑞他汀E（MMAE）相连。该vedotin连接子-有效载荷技术已在多种FDA批准的疗法中得到临床验证，包括brentuximab vedotin、enfortumab vedotin和tisotumab vedotin。

Felmetatug vedotin is currently in Phase I clinical trials for the treatment of advanced solid tumors such as ovarian, peritoneal, and triple-negative breast cancers, among others. Early results from the trial demonstrated objective responses in 7 of 28 breast cancer patients and 4 of 20 ovarian cancer patients.

费美他图单抗偶联物目前正处于治疗晚期实体瘤（如卵巢癌、腹膜癌和三阴性乳腺癌等）的I期临床试验中。试验的早期结果显示，在28名乳腺癌患者中有7名出现客观缓解，在20名卵巢癌患者中有4名出现客观缓解。

Additionally, 1 out of 16 patients with endometrial cancer achieved a complete response..

此外，16 名子宫内膜癌患者中有 1 名达到了完全缓解。

In

在

December 2023

2023年12月

, Pfizer finalized its acquisition of Seagen, purchasing all outstanding common shares for

，辉瑞公司完成了对Seagen的收购，购买了所有已发行的普通股。

$229

229美元

per share in cash, amounting to a total enterprise value of approximately

每股现金，总计企业价值约为

$43 billion

430亿美元

.

。

Emiltatug ledadotin

埃米利亚塔格·莱达多廷

is another B7-H4-targeting ADC, utilizing Mersana's Dolasynthen platform. It features a precisely engineered drug-to-antibody ratio (DAR) of 6 and a proprietary payload designed to deliver a controlled bystander effect. B7-H4 is highly expressed in several tumor types, including breast, ovarian, and endometrial cancers.

是另一种靶向B7-H4的ADC，利用了Mersana的Dolasynthen平台。它的药物抗体比（DAR）精确设计为6，并配备了专有的有效载荷，旨在实现可控的旁观者效应。B7-H4在多种肿瘤类型中高度表达，包括乳腺癌、卵巢癌和子宫内膜癌。

In 2022, Mersana launched a multicenter Phase I clinical trial to evaluate the safety, tolerability, and preliminary efficacy of emiltatug ledadotin in patients with solid tumors, including those affecting the breast, ovary, and endometrium. The U.S. FDA has granted Fast Track Designation to the drug for adults with advanced or metastatic triple-negative breast cancer..

2022年，Mersana启动了一项多中心I期临床试验，以评估emiltatug ledadotin在包括乳腺、卵巢和子宫内膜在内的实体瘤患者中的安全性、耐受性和初步疗效。美国FDA已授予该药物用于治疗晚期或转移性三阴性乳腺癌成人患者的快速通道资格。

Initial results from the Phase I trial indicated that emiltatug ledadotin was generally well tolerated. No Grade 4 or 5 treatment-related adverse events (TRAEs) were observed. The most common TRAEs of any grade included transient increases in AST (38%), asymptomatic and reversible proteinuria (31%), mild nausea (29%), and fatigue (28%).

I期试验的初步结果表明，emiltatug ledadotin总体耐受性良好。未观察到4级或5级治疗相关不良事件（TRAEs）。最常见的任何级别的TRAEs包括短暂的AST升高（38%）、无症状且可逆的蛋白尿（31%）、轻度恶心（29%）和疲劳（28%）。

Grade 3 TRAEs occurring in 5% or more of patients were limited to AST elevation (14%) and proteinuria (9%)..

3级TRAE发生在5%或以上的患者仅限于AST升高（14%）和蛋白尿（9%）。

The anticipated launch of these emerging therapies are poised to transform the B7-H4 Targeting Therapies market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the B7-H4 Targeting Therapies market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth..

这些新兴疗法的预期推出将在未来几年内改变B7-H4靶向治疗市场的格局。随着这些前沿疗法不断成熟并获得监管批准，它们有望重塑B7-H4靶向治疗市场，提供新的护理标准，并为医学创新和经济增长带来机遇。

To know more about B7-H4 targeting therapies clinical trials, visit @

要了解更多关于B7-H4靶向治疗的临床试验，请访问@

B7-H4 Targeting Therapies Treatment

B7-H4靶向治疗

B7-H4 Targeting Therapies Overview

B7-H4靶向治疗概述

B7-H4, a key member of the B7 protein family, is abnormally expressed in various conditions such as cancer, inflammation, and autoimmune disorders. It acts as a negative regulator of the T cell immune response, contributing to immune evasion by suppressing T cell proliferation, cytokine production, and cell cycle progression.

B7-H4是B7蛋白家族的关键成员，在癌症、炎症和自身免疫疾病等多种情况下异常表达。它作为T细胞免疫反应的负调节因子，通过抑制T细胞增殖、细胞因子产生和细胞周期进程，促进免疫逃逸。

B7-H4 is also critically involved in cancer initiation and progression, influencing processes like cell growth, invasion, metastasis, and resistance to cell death. Beyond oncology, B7-H4 plays additional biological roles, including protecting against type 1 diabetes and supporting islet cell transplantation.

B7-H4还与癌症的发生和发展密切相关，影响细胞生长、侵袭、转移和对细胞死亡的抵抗等过程。除了肿瘤学，B7-H4还具有其他生物学作用，包括预防1型糖尿病和支持胰岛细胞移植。

Given these functions, B7-H4 has gained attention as a potential biomarker and therapeutic target in cancer, immune-related diseases, and transplantation..

鉴于这些功能，B7-H4 已成为癌症、免疫相关疾病和移植中潜在的生物标志物和治疗靶点而受到关注。

As a transmembrane protein, B7-H4 has attracted significant interest in solid tumor therapy, particularly in the development of antibody-drug conjugates (ADCs) targeting this pathway. Notably, its overexpression has been documented in several cancers, including ovarian, lung, renal, breast, and gastric tumors.

作为一种跨膜蛋白，B7-H4在实体瘤治疗中引起了极大的关注，尤其是在开发针对该通路的抗体药物偶联物（ADC）方面。值得注意的是，已有研究表明其在多种癌症中过表达，包括卵巢癌、肺癌、肾癌、乳腺癌和胃癌。

Elevated B7-H4 levels in these cancers are often linked with larger tumor size, higher tumor grade, and reduced patient survival. Its role in tumor progression is mediated through multiple mechanisms, including enhanced proliferation, invasion, metastasis, and inhibition of apoptosis..

这些癌症中B7-H4水平升高通常与较大的肿瘤大小、较高的肿瘤等级和患者生存率降低有关。其在肿瘤进展中的作用通过多种机制介导，包括增强的增殖、侵袭、转移和抑制细胞凋亡。

B7-H4 Targeting Therapies Epidemiology Segmentation

B7-H4靶向治疗的流行病学细分

The B7-H4 targeting therapies market report proffers epidemiological analysis for the study period 2020–2040 in the 7MM, segmented into:

B7-H4靶向治疗市场报告提供了2020年至2040年研究期间在七大主要市场（7MM）中的流行病学分析，具体细分如下：

Total Cases of Selected Indications for B7-H4

B7-H4选定适应症的总病例数

Total Eligible Patient Pool of Selected Indications for B7-H4

针对B7-H4选定适应症的总合格患者池

Total Treated Cases of Selected Indications for B7-H4

B7-H4选定适应症的总治疗病例数

B7-H4 Targeting Therapies Report Metrics

B7-H4靶向治疗报告指标

Details

详情

Study Period

学习期

2020–2040

2020–2040

B7-H4 Targeting Therapies Report Coverage

B7-H4靶向治疗报告覆盖范围

7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]

七国集团 [美国、欧盟四国（德国、法国、意大利和西班牙）、英国和日本]

Key Indications Covered in the Report

报告中涵盖的关键适应症

NSCLC, Ovarian Cancer, Endometrial Cancer, Triple Negative Breast Cancer, Biliary Tract Cancer, and others

非小细胞肺癌、卵巢癌、子宫内膜癌、三阴性乳腺癌、胆道癌等

Key B7-H4 Targeting Therapies Companies

关键B7-H4靶向治疗公司

AstraZeneca, Pfizer (Seagen), Mersana Therapeutics, GlaxoSmithKline, NextCure, and others

阿斯利康、辉瑞（Seagen）、Mersana Therapeutics、葛兰素史克、NextCure 等公司

Key B7-H4 Targeting Therapies

关键的B7-H4靶向疗法

Puxitatug samrotecan (AZD8205), Felmetatug vedotin, Emiltatug ledadotin, GSK5733584, LNCB74, and others

Puxitatug samrotecan (AZD8205)、Felmetatug vedotin、Emiltatug ledadotin、GSK5733584、LNCB74 等其他药物

Scope of the

范围

B7-H4 Targeting Therapies

B7-H4靶向治疗

Market Report

市场报告

B7-H4 Targeting Therapies Therapeutic Assessment:

B7-H4靶向疗法治疗评估：

B7-H4 Targeting Therapies current marketed and emerging therapies

B7-H4靶向治疗 当前已上市和新兴疗法

B7-H4 Targeting Therapies

B7-H4靶向治疗

Market Dynamics:

市场动态：

Conjoint Analysis of Emerging B7-H4 Targeting Therapies Drugs

新兴B7-H4靶向治疗药物的联合分析

Competitive Intelligence Analysis:

竞争情报分析：

SWOT analysis and Market entry strategies

SWOT分析与市场进入策略

Unmet Needs, KOL's views, Analyst's views, B7-H4 Targeting Therapies Market Access and Reimbursement

未满足的需求、关键意见领袖的观点、分析师的观点、B7-H4靶向治疗市场的准入与报销

Discover more about B7-H4 targeting therapies in development @

了解更多关于正在开发中的B7-H4靶向疗法 @

B7-H4 Targeting Therapies Clinical Trials

B7-H4靶向治疗临床试验

Table of Contents

目录

1

1

Key Insights

关键见解

2

2

Report Introduction

报告介绍

3

3

Executive Summary of B7-H4

B7-H4的执行摘要

4

4

Key Events

关键事件

5

5

Market Forecast Methodology

市场预测方法论

6

6

B7-H4 Market Overview at a Glance in the 7MM

7MM中B7-H4市场概况一览

6.1

6.1

Market Share (%) Distribution by Therapies in 2027

2027年各疗法市场份额（%）分布

6.2

6.2

Market Share (%) Distribution by Therapies in 2040

2040年各疗法市场份额（%）分布

6.3.

6.3.

Market Share (%) Distribution by Indications in 2027

2027年按适应症划分的市场份额（%）分布

6.4

6.4

Market Share (%) Distribution by Indications in 2040

2040年按适应症划分的市场份额（%）分布

7

7

B7-H4: Background and Overview

B7-H4：背景与概述

8

8

Target Patient Pool

目标患者群体

8.1

8.1

Key Findings

主要发现

8.2

8.2

Assumptions and Rationale: 7MM

假设与理由：7MM

8.3

8.3

Epidemiology Scenario in the 7MM

七大市场（7MM）的流行病学情景

8.3.1

8.3.1

Total Cases of Selected Indication for B7-H4 in the 7MM

7MM中B7-H4选定适应症的总病例数

8.3.2

8.3.2

Total Eligible Patient Pool for B7-H4 in Selected Indication in the 7MM

7MM中选定适应症的B7-H4总合格患者池

8.3.3

8.3.3

Total Treatable Cases in Selected Indications for B7-H4 in the 7MM

7MM中B7-H4在选定适应症中的总可治疗病例数

9

9

Emerging Therapies

新兴疗法

9.1

9.1

Key Competitors

主要竞争对手

9.2

9.2

Felmetatug vedotin:  Pfizer (Seagen)

费奈妥珠单抗：辉瑞（Seagen）

9.2.1

9.2.1

Product Description

产品描述

9.2.2

9.2.2

Other developmental activities

其他开发活动

9.2.3

9.2.3

Clinical development

临床开发

9.2.4

9.2.4

Safety and efficacy

安全性与有效性

9.3

9.3

Emiltatug ledadotin: Mersana Therapeutics

埃米利塔图格·莱达多廷：梅萨纳治疗学公司

9.3.1

9.3.1

Product Description

产品描述

9.3.2

9.3.2

Other developmental activities

其他开发活动

9.3.3

9.3.3

Clinical development

临床开发

9.3.4

9.3.4

Safety and efficacy

安全性与有效性

List to be continued in the report…

报告中待续的列表…

10

10

B7-H4: Seven Major Market Analysis

B7-H4：七大市场分析

10.1

10.1

Key Findings

关键发现

10.2

10.2

Market Outlook

市场展望

10.3

10.3

Conjoint Analysis

联合分析

10.4

10.4

Key Market Forecast Assumptions

主要市场预测假设

10.4.1

10.4.1

Cost Assumptions and Rebates

成本假设与回扣

10.4.2

10.4.2

Pricing Trends

定价趋势

10.4.3

10.4.3

Analogue Assessment

模拟评估

10.4.4

10.4.4

Launch Year and Therapy Uptakes

上市年份与治疗吸收情况

10.5

10.5

Total Market Size of B7-H4 in the 7MM

B7-H4在七大市场中的总市场规模

10.6

10.6

The United States

美国

10.7

10.7

EU4 and the UK

EU4 和英国

10.8

10.8

Japan

日本

11

11

SWOT Analysis of B7-H4

B7-H4的SWOT分析

12

12

KOL Views of B7-H4

KOL对B7-H4的看法

13

13

Unmet Needs of B7-H4

B7-H4的未满足需求

14

14

Market Access and Reimbursement

市场准入与报销

15

15

Bibliography

参考文献

16

16

Report Methodology

报告方法论

Related Reports

相关报告

Non-Small Cell Lung Cancer Market

非小细胞肺癌市场

Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2034

非小细胞肺癌市场洞察、流行病学和市场预测 - 2034年

report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies, including

报告深入介绍了该疾病、历史和预测的流行病学，以及市场趋势、市场驱动因素、市场壁垒和主要的非小细胞肺癌公司，包括

AstraZeneca, Boehringer Ingelheim, Pfizer, Takeda, Johnson & Johnson Innovative Medicine, Eli Lilly and Company, Merck, Bristol-Myers Squibb, Roche, Shanghai Henlius Biotech, AbbVie, Daiichi Sankyo, Nuvation Bio, PDC*line Pharma, Moderna Therapeutics, Pfizer, GSK, Gilead Sciences, BieGene, Nuvalent,.

阿斯利康、勃林格殷格翰、辉瑞、武田、强生创新制药、礼来公司、默克、百时美施贵宝、罗氏、上海复宏汉霖生物技术、艾伯维、第一三共、努瓦森生物、PDC*line制药、莫德纳治疗学、辉瑞、葛兰素史克、吉利德科学、BieGene、Nuvalent。

among others.

其中包括。

Triple Negative Breast Cancer Market

三阴性乳腺癌市场

Triple Negative Breast Cancer Market Insights, Epidemiology, and Market Forecast – 2034

三阴性乳腺癌市场洞察、流行病学与市场预测——2034

report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key TNBC companies, including

报告深入介绍了该疾病、历史和预测的流行病学情况，以及市场趋势、市场驱动因素、市场障碍和主要的三阴性乳腺癌（TNBC）公司，包括

AstraZeneca, Daiichi Sankyo, OBI Pharma, Astellas Pharma, Pfizer, Galera Therapeutics, BioNTech,

阿斯利康、第一三共、浩鼎生技、安斯泰来制药、辉瑞、加莱拉治疗、生物恩泰克，

among others.

其中包括。

Endometrial Cancer Market

子宫内膜癌市场

Endometrial Cancer Market Insights, Epidemiology, and Market Forecast – 2034

子宫内膜癌市场洞察、流行病学及市场预测——2034年

report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endometrial cancer companies, including

报告深入介绍了该疾病、历史和预测的流行病学，以及市场趋势、市场驱动因素、市场障碍和关键的子宫内膜癌公司，包括

GlaxoSmithKline, Merck & Co, AstraZeneca, Karyopharm Therapeutics, Evergreen Therapeutics, Incyte Corporation,

葛兰素史克、默克公司、阿斯利康、凯瑞制药、长青制药、因赛特公司，

among others.

其中包括。

Biliary Tract Cancer Market

胆道癌市场

Biliary Tract Cancer Market Insights, Epidemiology, and Market Forecast – 2034

胆道癌市场洞察、流行病学与市场预测——2034

report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key biliary tract cancer companies, including

报告深入介绍了该疾病、历史和预测的流行病学，以及市场趋势、市场驱动因素、市场障碍和关键胆道癌公司，包括

Compass Therapeutics, Jazz Pharmaceuticals, Zymeworks, AstraZeneca, Daiichi Sankyo, Merck Sharp & Dohme, Eisai, Senhwa Biosciences, Seagen, Pfizer, TransThera Sciences, Compugen, Bold Therapeutics,

Compass Therapeutics、Jazz Pharmaceuticals、Zymeworks、阿斯利康、第一三共、默沙东、卫材、Senhwa Biosciences、Seagen、辉瑞、TransThera Sciences、Compugen、Bold Therapeutics，

among others.

其中包括。

About DelveInsight

关于DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

德尔维洞察是一家领先的商业咨询和市场研究公司，专注于生命科学领域。它通过提供全面的端到端解决方案来支持制药公司以提升其业绩。通过我们的订阅平台 PharmDelve，您可以轻松获取所有医疗保健和制药市场研究报告。

.

。

Contact Us

联系我们

Shruti Thakur

舒鲁蒂·塔库尔

info@delveinsight.com

info@delveinsight.com

+14699457679

+14699457679

Logo:

标志：

https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP

来源：DelveInsight商业研究公司

WANT YOUR COMPANY'S NEWS

想要你公司的新闻

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers

影响者

9k+

9k+

Digital Media

数字媒体

Outlets

插座

270k+

27万+

Journalists

记者

Opted In

已选择加入

GET STARTED

开始使用